Adherex Technologies, Inc.

FDA clears IND for Exherin

Published in Food and Drug Law Weekly, July 30th, 2004

Adherex Technologies, Inc., (AHX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Exherin, the company's lead cadherin antagonist, tumor vascular targeting compound; this means the company is able to commence a U.S.-based, phase I clinical trial of Exherin.

The study will take place under the direction of David J. Stewart, MD, professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas M.D. Anderson Cancer Center in Houston.

Vascular targeting is a novel approach to cancer treatment, said David Stewart, Principal Investigator for the study....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2004-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry